Grifols begins manufacturing potential COVID-19 treatment at Clayton facility
Date Published:
CLAYTON – Grifols, a global biotherapeutics company with major operations in North Carolina, has begun producing the first specific COVID-19…
Johnston County
Grifols to invest $356M for new facility in Clayton, adding hundreds of jobs
Date Published:
CLAYTON — Grifols, a global biotherapeutics company with already more than 2,000 employees in North Carolina, is investing $351.6 million…
Diagnosed with COVID-19 and recovered? Here’s a chance to contribute to pandemic fight
Date Published:
RESEARCH TRIANGLE PARK – If you’ve been diagnosed with the COVID-19 coronavirus and have recovered, you can help researchers find…
Grifols begins accepting plasma from recovered COVID-19 patients
Date Published:
Grifols is now accepting plasma from volunteer donors who have recovered from the COVID-19 virus at its Raleigh area locations.…
Grifols pursues development of coronavirus treatment based on blood plasma
Date Published:
RESEARCH TRIANGLE PARK – Grifols, a global biotherapeutics company with more than 2,000 employees in North Carolina, will produce and…
Grifols Clayton Plant Working On Coronavirus Vaccine
Date Published:
Grifols volunteers to engage in a public-private sector partnership in an effort to develop a vaccine for COVID-19
Read more…
Novo Nordisk invests in new $40M wastewater plant, turns over to Clayton to help spur BioPharma Crescent growth
Date Published:
CLAYTON – A public-private partnership has cut the ribbon for a regional industrial wastewater pretreatment facility in Clayton worth $40…
161-Job Furniture Expansion in Johnston County
Date Published:
Johnston County, N.C. – May 28, 2019
Broad River Retail LLC will establish a major distribution facility, customer contact center…
Danish Insulin Maker in Johnston County Will Invest $22 Million as BioPharma Crescent Draws Attention
Date Published:
JOHNSTON COUNTY COMMISSIONERS APPROVE INCENTIVES FOR LATEST NOVO NORDISK EXPANSION
Johnston County, N.C. – December 3, 2018. Novo Nordisk, which…